AI Drug Discovery: Turbine Secures $25M to Revolutionize Biopharma with Virtual Biology
February 27, 2026, 5:14 pm
Turbine, the innovative virtual biology company based in Budapest, just secured $25 million in Series B funding. This significant capital infusion, spearheaded by Interactive Venture Partners and backed by Beiersdorf Venture Capital, accelerates the company's pioneering mission. Turbine's AI-powered virtual cell platform is revolutionizing drug discovery and development. It digitally models biological experiments, significantly improving speed and efficiency in biopharma R&D. The new funds fuel platform expansion, adding diverse assays across discovery and translational medicine. Crucially, Turbine extends its therapeutic focus beyond oncology, initiating a major immunology partnership with a global pharmaceutical leader. Its Virtual Lab enables rapid, large-scale in silico experimentation, testing millions of hypotheses. This strategic investment underscores Turbine's potential to redefine pharmaceutical research, delivering faster, more effective treatments to patients globally.
Turbine, a leading virtual biology company, announced a major funding milestone. It successfully raised $25 million in Series B financing. This significant capital injection will fuel accelerated growth. The investment solidifies Turbine's position in the AI drug discovery sector. Interactive Venture Partners led the funding round. Beiersdorf Venture Capital also participated. Existing investors like MSD Global Health Innovation, Accel, and Mercia reaffirmed their support.
The Budapest-headquartered firm is transforming pharmaceutical research. It leverages artificial intelligence to virtualize complex biological experiments. This unique approach bypasses traditional lab constraints. Turbine's foundational technology is a sophisticated virtual cell model. This model creates digital copies of experimental assays. These virtual assays accelerate drug discovery. They also enhance clinical translatability.
New funds will drive platform expansion. Turbine plans to virtualize additional assays. This covers both early discovery and translational medicine. The company employs a "lab-in-the-loop" strategy. This generates proprietary perturbation datasets. These datasets refine the virtual cell model. They extend its application across new assay and tissue types.
Turbine's Virtual Lab is a key offering. It is a no-code platform. The Virtual Lab integrates seamlessly into pharmaceutical workflows. It empowers researchers to run experiments at computational speed. Millions of hypotheses can be tested rapidly. This scale is impossible in traditional wet labs. It represents a paradigm shift for biopharma R&D.
The company has already made significant impacts. It partners with major biopharma organizations. MSD (Merck & Co.), AstraZeneca, and Bayer are among them. Turbine’s virtual assays have supported over 30 discovery programs. These collaborations demonstrate the technology's effectiveness. They validate its real-world utility in drug development.
A strategic expansion into immunology is now underway. Turbine previously focused on oncology. The company unveiled its first immunology-focused partnership. A top 10 global pharmaceutical company is its new collaborator. This move broadens Turbine's therapeutic reach significantly. The partnership aims to model immune cell behavior. It uses proprietary datasets from the pharma partner.
This immunology collaboration has clear objectives. It seeks to generate mechanistic insights into immune pathways. This will help identify novel therapeutic combinations. Large-scale in silico experimentation is central to this effort. Only the highest-conviction hypotheses will proceed to wet-lab validation. This ensures efficiency and reduces research waste.
The investment reflects strong confidence in Turbine's vision. Interactive Venture Partners brings deep industry knowledge. Its affiliation with Interactive Brokers Group highlights significant backing. Beiersdorf Venture Capital sees potential in AI-driven technologies. They recognize how virtual cell models assess ingredient interactions with skin biology. This aligns with Beiersdorf's skincare focus.
Turbine’s technology addresses critical challenges. Drug discovery is notoriously expensive and time-consuming. AI-powered platforms offer a powerful solution. They drastically cut down development timelines. They also reduce costs. Virtualization allows for systematic exploration of drug interactions. This accelerates identification of effective treatments.
The company aims to build an active learning loop. Simulations inform precise wet lab experiments. These experiments generate data. That data improves subsequent predictions. This iterative process refines therapeutic insights. Ultimately, it identifies successful drug combinations. This approach applies to complex immunological diseases. It also targets specific patient cohorts.
This Series B funding positions Turbine for aggressive growth. It will bolster its team and technological capabilities. The expansion into immunology opens vast new market opportunities. The demand for innovative solutions in biopharma remains high. Turbine is at the forefront of this revolution. Its virtual biology platform promises faster, more effective therapies. This benefits patients worldwide. The future of drug discovery is increasingly digital. Turbine leads the charge.
Turbine, a leading virtual biology company, announced a major funding milestone. It successfully raised $25 million in Series B financing. This significant capital injection will fuel accelerated growth. The investment solidifies Turbine's position in the AI drug discovery sector. Interactive Venture Partners led the funding round. Beiersdorf Venture Capital also participated. Existing investors like MSD Global Health Innovation, Accel, and Mercia reaffirmed their support.
The Budapest-headquartered firm is transforming pharmaceutical research. It leverages artificial intelligence to virtualize complex biological experiments. This unique approach bypasses traditional lab constraints. Turbine's foundational technology is a sophisticated virtual cell model. This model creates digital copies of experimental assays. These virtual assays accelerate drug discovery. They also enhance clinical translatability.
New funds will drive platform expansion. Turbine plans to virtualize additional assays. This covers both early discovery and translational medicine. The company employs a "lab-in-the-loop" strategy. This generates proprietary perturbation datasets. These datasets refine the virtual cell model. They extend its application across new assay and tissue types.
Turbine's Virtual Lab is a key offering. It is a no-code platform. The Virtual Lab integrates seamlessly into pharmaceutical workflows. It empowers researchers to run experiments at computational speed. Millions of hypotheses can be tested rapidly. This scale is impossible in traditional wet labs. It represents a paradigm shift for biopharma R&D.
The company has already made significant impacts. It partners with major biopharma organizations. MSD (Merck & Co.), AstraZeneca, and Bayer are among them. Turbine’s virtual assays have supported over 30 discovery programs. These collaborations demonstrate the technology's effectiveness. They validate its real-world utility in drug development.
A strategic expansion into immunology is now underway. Turbine previously focused on oncology. The company unveiled its first immunology-focused partnership. A top 10 global pharmaceutical company is its new collaborator. This move broadens Turbine's therapeutic reach significantly. The partnership aims to model immune cell behavior. It uses proprietary datasets from the pharma partner.
This immunology collaboration has clear objectives. It seeks to generate mechanistic insights into immune pathways. This will help identify novel therapeutic combinations. Large-scale in silico experimentation is central to this effort. Only the highest-conviction hypotheses will proceed to wet-lab validation. This ensures efficiency and reduces research waste.
The investment reflects strong confidence in Turbine's vision. Interactive Venture Partners brings deep industry knowledge. Its affiliation with Interactive Brokers Group highlights significant backing. Beiersdorf Venture Capital sees potential in AI-driven technologies. They recognize how virtual cell models assess ingredient interactions with skin biology. This aligns with Beiersdorf's skincare focus.
Turbine’s technology addresses critical challenges. Drug discovery is notoriously expensive and time-consuming. AI-powered platforms offer a powerful solution. They drastically cut down development timelines. They also reduce costs. Virtualization allows for systematic exploration of drug interactions. This accelerates identification of effective treatments.
The company aims to build an active learning loop. Simulations inform precise wet lab experiments. These experiments generate data. That data improves subsequent predictions. This iterative process refines therapeutic insights. Ultimately, it identifies successful drug combinations. This approach applies to complex immunological diseases. It also targets specific patient cohorts.
This Series B funding positions Turbine for aggressive growth. It will bolster its team and technological capabilities. The expansion into immunology opens vast new market opportunities. The demand for innovative solutions in biopharma remains high. Turbine is at the forefront of this revolution. Its virtual biology platform promises faster, more effective therapies. This benefits patients worldwide. The future of drug discovery is increasingly digital. Turbine leads the charge.